Will a drug from completely different diseases help with cellulite?
A drug for penis curvature was sent to fight cellulite
As reported in the company's press release (Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite), Xiaflex is approved for use in the United States, Canada, Australia and the European Union for the treatment of patients with Dupuytren's contracture (scarring of palmar tendons due to excessive connective tissue development), and in the USA – with Peyronie's disease (curvature of the penis due to the growth of connective tissue and its degeneration into scar tissue). These diseases are united by a similar biological mechanism associated with the overproduction of collagen (connective tissue protein), which is affected by Xiaflex. The drug is a combination of two subtypes of the collagenase enzyme that destroys excess collagen, isolated from Clostridium histolyticum bacteria.
With cellulite affecting 85 to 98 percent of women, structural disorders occur in the subcutaneous fat associated with loss of elasticity of the collagen strands connecting the dermis and the underlying muscle layer. With an increase in the volume of subcutaneous fat, the collagen strands do not stretch enough or at all, which causes the so-called "orange peel effect" - the surface of the skin, mainly the parts of the body with the largest fat deposits - the hips and buttocks, becomes uneven, bumps and depressions appear on it. Despite the existence of numerous cosmetic procedures aimed at improving the condition of the skin, there is no scientifically confirmed evidence of their effectiveness.
Xiaflex injections into the areas affected by cellulite, as the developers believe, helps to dissolve the tightening collagen strands, ideally leading to a complete smoothing of the skin. In a double-blind study, 150 women aged 18 to 45 years suffering from cellulite received three rounds of Xiaflex or placebo injections into problem areas (hips or buttocks) at intervals of 21 days. During each therapeutic session, each participant received up to 12 injections with varying dosages.
The effectiveness of therapy was evaluated by a specially adapted Global Scale of Aesthetic Improvement (GAIS), which allows researchers and participants to determine the severity of changes occurring with the skin. As a result, it was found that in the group receiving the drug, the manifestations of cellulite significantly decreased, both from the point of view of the researchers and from the point of view of the participants. 68 percent of them rated their satisfaction with the results of therapy as high and very high. There were 34 percent of them in the placebo group. At the same time, no serious side effects of the use of Xiaflex were detected.
After the news of the test results, the share price of Auxilium Pharmaceuticals soared up, as the potential market volume for the anti-cellulite use of Xiaflex is estimated in billions of dollars. The company plans to conduct the second phase of the second phase of its clinical trials on a wider range of participants in early 2015.
Portal "Eternal youth" http://vechnayamolodost.ru25.08.2014